The mechanism of acquisition of cancer metastatic capacity in peritoneal free cancer cells disseminated by cancer surgery and development of treatment for these cancer cells

2017 Fiscal Year Final Research Report

• Project/Area Number: 15K10096
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Digestive surgery
• Research Institution: Shiga University of Medical Science
• Principal Investigator: Murata Satoshi 滋賀医科大学, 医学部, 講師 (90239525)
• Co-Investigator(Kenkyū-buntansha): 山本 寛 滋賀医科大学, 医学部, 非常勤講師 (00283557) ; 山口 剛 滋賀医科大学, 医学部, 助教 (10510290) ; 谷 眞至 滋賀医科大学, 医学部, 教授 (60236677) ; 清水 智治 滋賀医科大学, 医学部, 准教授 (70402708) ; 三宅 亨 滋賀医科大学, 医学部, 助教 (70581924)
• Research Collaborator: KODAMA Hirokazu ; TAKEBAYASHI Katsushi ; ARIKAWA Ikuko ; YAMAMOTO Miho
• Project Period (FY): 2015-04-01 – 2018-03-31
• Keywords: 腹膜転移 / 腹腔内遊離癌細胞 / 癌幹細胞 / 腹腔内治療

Outline of Final Research Achievements

The purpose of the study was to elucidate the mechanism of peritoneal recurrences after curative gastric cancer (GC) surgery, and also to develop an effective therapy for source of cancer recurrence. Viable cancer cells that could cause peritoneal recurrence existed in the invasive serosa surface, lymphatic or blood vessels, and also in the residual gastric lumen after gastrectomy. These cancer cells contained cancer stem-like cells expressing CD44, and cancer recurrence occurred only in cases where cancer cells were detected in the intraperitoneal lavage fluid during GC surgery. Hyperthermic intraperitoneal chemotherapy (HIPEC) targeting intraoperatively spilled cancer cells significantly inhibited postoperative recurrence. GC surgery disseminated cancer cells including cancer stem-like cells into the peritoneal cavity, and these spilled cancer cells have been the source of cancer recurrence. We found that this source of cancer recurrence can be effectively treated by HIPEC.

Free Research Field

消化器外科学